Allogene Therapeutics (ALLO) Q4 2024 Annual Earnings
ALLO·Reported March 13, 2025·After market close
Allogene Therapeutics reported Q4 2024 revenue of $22.0K, beat analyst consensus of $12.0K by $10.0K. Diluted EPS came in at $-0.28, beat the $-0.34 consensus by $0.06.
Revenue
$22.0Kbeat by $10.0K
Consensus: $12.0KDiluted EPS
$-0.28beat by $0.06
Consensus: $-0.34
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Allogene Therapeutics's Q4 2024 earnings report.
Allogene Therapeutics (ALLO) reported Q4 2024 earnings on March 13, 2025 after market close.
Allogene Therapeutics reported revenue of $22.0K and diluted EPS of $-0.28 for Q4 2024.
Revenue beat the consensus estimate of $12.0K by $10.0K. EPS beat the consensus estimate of $-0.34 by $0.06.
You can read the 10-K periodic report (0001737287-25-000036) directly on SEC EDGAR. The filing index links above go to sec.gov.